Council For Advanced Regenerative Medicine (CARM) Completes First Corporate and Technology Exchange 

The Council For Advanced Regenerative Medicine (CARM), a leading organization in Korea's advanced regenerative medicine industry, announced today that it successfully held its first corporate and technology exchange event with 20 member companies.

The event, organized by CARM's Corporate Exchange Committee, was held at the Xcell Therapeutics Lounge in Daechi-dong, Gangnam-gu, Seoul, on the 27th.

In his greeting, Chairman Kang Kyung-sun (Professor of Veterinary Medicine at Seoul National University and Founder of Kangstem Biotech) said, "In order to create synergies with each other, we must first understand each other." He added, "I hope that through the exchange meeting, we can improve our understanding of each company's advanced biotechnology and build mutual trust."

The event began with an invited lecture on 'IPO Preparation Strategies' by Mr. Lee Sung-gil, who served as the head of the Corporate Listing Department at the Korea Exchange, followed by company introductions by member companies Ilyas Biologics and Daewoong Pharmaceutical, and many attendees asked questions after Mr. Lee's lecture, indicating their high interest in going public.

During the networking time that followed the official event, all participants had a meaningful time to mingle and promote mutual understanding.

"CARM's Company-Technology Exchange will continue to be held every other month (June, August, October, and December) until the end of the year to build mutual understanding and trust among companies leading the regenerative medicine industry," said Lee Yi-il, Chairman of the Company Exchange Committee (Xcell Therapeutics). "We will do our best to make the Company-Technology Exchange a venue for open innovation through activating exchanges between companies."

Meanwhile, the Council For Advanced Regenerative Medicine (CARM) is a business-oriented organization that aims to revitalize the domestic regenerative medicine industry and lead the global regenerative medicine market, and was launched in 2016.

The association strives to support the national budget and improve regulations for the development of the domestic advanced regenerative medicine industry and to revitalize investment in related companies. In particular, it worked to pass the Advanced Regenerative Bio Act in the National Assembly in 2018 and contributed to the passage of a preliminary feasibility study of KRW 600 billion in 2020 for advanced regenerative medicine research and industry, as well as the establishment of the Advanced Regenerative Medicine Business Unit in 2021.

The association's subcommittees include the External Cooperation Committee, Policy Committee, and Corporate Exchange Committee, and the Corporate Exchange Committee, which organized the company-technology exchange, aims to find ways to support venture and startup companies in the field of regenerative medicine and contribute to building an integrated and sustainable industrial ecosystem through expanding exchanges between the corporate and public sectors.

Source : Biotimes (http://www.biotimes.co.kr)